US · Health Care
Viatris stock overview: financials, insider activity, and peer context
Viatris operates in the Pharmaceuticals industry within the Health Care sector and is a constituent of the S&P 500. This page connects filing evidence with ownership, insider activity, forecasts, ETFs, and peer context so each dataset can be checked against the others.
Deterministic, source-linked commentary
VTRS signals across filings and ownership
VTRS's current operating picture begins with the latest company report. 10-Q covers CY2026Q1. quarterly revenue was $3.5B; year-over-year growth was 8.2%; operating margin was -2.3%; trailing free cash flow was $1.9B. Read together, these figures test whether scale is translating into profit and cash. Verify periods and company footnotes in the original SEC EDGAR filing.
Viatris is easier to assess when each disclosure is read on its own clock. Use institutional ownership, insider filings alongside the filing. Company facts can update before 13F positions, so align every source date and report period before treating a difference as a change in fundamentals.
Business model
Company snapshot
Viatris operates in the Pharmaceuticals industry within the Health Care sector and is a constituent of the S&P 500. The latest standardized snapshot records $14.07B of trailing revenue, -$169.9M of net income, and $1.9B of free cash flow. These figures describe the reported company, while valuation and price require a separate market-data timestamp.
Operating lines
A named product, service, or operating exposure identified in the company description.
A named product, service, or operating exposure identified in the company description.
Geographic revenue mix
The current standardized filing dataset does not extract a comparable geographic revenue table for every issuer. Review the latest 10-K segment note for domestic and international mix, concentration, foreign-exchange sensitivity, and country-specific regulation.
10-Q · 2026-05-07
What the latest filing shows
Revenue for the latest standardized quarter was $3.51B, while diluted EPS was 0.15. Revenue changed 8.2% from the comparable period. Gross margin was 33% and operating margin was -2.3%. Margin direction matters because it shows whether growth is translating into operating leverage or requiring more cost to support.
Open original SEC filingCY2026Q1
Earnings analysis
| Period | Revenue | Net income | EPS | Operating margin |
|---|---|---|---|---|
| CY2026Q1 | $3.51B | -$169M | 0.15 | -2.3% |
| TTM | $14.07B | -$169.9M | -2.51 | -18.1% |
| CY2025 | $14.25B | $0 | See filing | -18.7% |
The standardized data shows revenue growth of 8.2%, an operating margin of -18.1%, and a net margin of -1.2%. Without a dedicated earnings article, the original filing remains the primary source for management guidance and expectation comparisons.
Health Care
Peer comparison
| Company | TTM revenue | Revenue growth | Operating margin | Tracked holders |
|---|---|---|---|---|
| VTRSViatris | $14.07B | 8.2% | -18.1% | 0 |
| REGNRegeneron Pharmaceuticals | $14.06B | 19% | 23.8% | 0 |
| LHLabcorp | $13.97B | 5.8% | 10.7% | 0 |
| DVADaVita | $13.44B | 6% | 14.6% | 1 |
| HSICHenry Schein | $13.12B | 6.3% | 5.1% | 0 |
| IQVIQVIA | $16.1B | 8.4% | 12.9% | 0 |
| VRTXVertex Pharmaceuticals | $11.8B | 7.8% | 34.8% | 0 |
VTRS's 8.2% revenue growth and -18.1% operating margin should be read against peers using the same reporting definitions. A higher margin may reflect pricing power or business mix, while a lower margin can reflect investment, cyclicality, or weaker economics.
10-K · 2026-02-26
Key risk factors disclosed in the latest 10-K
The categories below are a deterministic research checklist anchored to Viatris's industry and latest annual filing. They summarize areas investors should locate in Item 1A; they do not replace the company's exact legal disclosure.
- Demand and product-cycle risk: Pharmaceuticals can experience changing customer demand, replacement cycles, and competitive product launches that affect revenue timing.
- Competition and execution: Market share depends on product quality, pricing, distribution, innovation, and management's ability to convert investment into durable customer demand.
- Supply chain and counterparties: Supplier concentration, logistics disruption, component availability, and customer concentration can affect delivery schedules, costs, and working capital.
- Regulation and litigation: Antitrust, privacy, securities, labor, tax, environmental, and industry-specific rules may change costs or restrict products and business practices.
- Financial and market risk: Foreign exchange, interest rates, credit conditions, investment values, and capital-allocation decisions can affect reported earnings and valuation.
Research workflow
Common research questions about VTRS
Who is the largest tracked institutional holder of VTRS?
The current tracked-manager sample does not identify an active VTRS holder. The VTRS ownership page will reflect a matching position when one enters the filing dataset.
What does recent insider activity show for VTRS?
No recent Form 4 transaction appears in the current VTRS window. Check the VTRS Form 4 history for later company-officer or director filings.
What business does Viatris operate?
Viatris operates in the Pharmaceuticals industry within the Health Care sector and is a constituent of the S&P 500. The VTRS company snapshot connects that business description with reported revenue, profit, and cash flow.
How does VTRS compare with a close operating peer?
VTRS's revenue growth is 8.2% and its operating margin is -18.1%. Compare those figures with REGN research using the same definitions.
What do the latest financials say about VTRS?
10-Q reports $14.1B of trailing revenue, with revenue growth of 8.2% and an operating margin of -18.1%. The supporting period and source are listed in the VTRS filing section.
How strong is VTRS's cash return profile?
Viatris does not show a positive trailing dividend cash outflow in the standardized snapshot, while free cash flow is $1.9B. Review the VTRS filing evidence before assessing capital-allocation capacity.
Which reported changes matter most for the VTRS outlook?
Without a dedicated forecast, the key VTRS evidence is the direction of revenue, margin, cash flow, and company guidance. The VTRS earnings section keeps those reported changes together.
Primary and reference data
Sources and methodology
- Filings: SEC EDGAR CompanyFacts, 10-K, 10-Q, 8-K, Form 4, 13F-HR.
- Fundamentals: SEC EDGAR CompanyFacts; market references may use yfinance and Finnhub where explicitly available.
- ETF: Issuer disclosures and the locally dated ETF holdings snapshot.
Methodology: How SnowballHare parses and validates data.
Editorial standards: How research is published.
Disclaimer: Informational only; not investment, legal, or tax advice. Cross-check material facts against original filings before acting.
Reference notes
Data notes
Reporting dates
Use filing dates, report periods, and source links together for VTRS. A company filing, a 13F disclosure, a Form 4 transaction, and an earnings release can describe different time windows, so the date beside each row matters before comparing signals.
Ownership context
13F rows are delayed public long-equity snapshots from a selected manager universe. They are useful for seeing which tracked institutions reported exposure, but they do not show every hedge, short position, cash balance, or trade made after the quarter ended.
Insider transactions
Form 4 activity should be read by transaction type, role, value, and remaining ownership. Open-market purchases and sales are different from grants, option exercises, gifts, or tax withholding, and the original SEC filing is still the controlling document.
Earnings and forecasts
Earnings pages and forecast pages are linked when a supported article exists. Treat those pages as context for reported numbers, guidance, margins, and scenario assumptions, then return to the table data when you need the underlying source date or filing trail.